Hikal Peer Comparison

Hikal Ltd. is underperforming relative to its peers in the Pharmaceuticals & Drugs sector, showing negative revenue growth and lower profitability metrics. Its valuation metrics also suggest it may be overvalued compared to its growth prospects, which are declining.

• • Hikal Ltd. has the lowest revenue growth YoY and lowest EPS among peers.
• • The company exhibits lower ROE and ROA compared to its peers, indicating weaker profitability.
• • Hikal's PE ratio is high relative to its growth, suggesting it may be overvalued.
• • Key peers like Cipla and Dr. Reddy's show strong profitability and solid growth, making them attractive investment options.

• • Cipla Ltd.: Strong revenue growth and profitability metrics with attractive valuation ratios.
• • Dr. Reddy's Laboratories Ltd.: High ROE and ROA with very low PE ratio, indicating good value and strong business performance.
• • Mankind Pharma Ltd.: Exceptional revenue growth and solid profitability metrics, despite moderate valuation.